Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
57 hedge funds and large institutions have $163M invested in Alder Biopharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 4 closing their positions.
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
16% more funds holding
Funds holding: 49 → 57 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less capital invested
Capital invested by funds: $220M → $163M (-$56.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$17.2M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.47M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.27M |
| 4 |
PC
PointState Capital
New York
|
+$1.51M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$2.27M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.01M |
| 3 |
Morgan Stanley
New York
|
-$1.18M |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
-$283K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$231K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| $18K | +$20.8K | +1,374 | +781% |
|
|
52
Morgan Stanley
New York
| $15K | -$1.18M | -78,104 | -98% |
|
|
LTFS
53
Ladenburg Thalmann Financial Services
Miami,
Florida
| $11K | -$86.9K | -5,750 | -87% |
|
54
Creative Planning
Overland Park,
Kansas
| $8K | +$9.04K | +598 | New |
|
|
MAA
55
Managed Account Advisors
Jersey City,
New Jersey
| $6K | -$45 | -3 | -0.7% |
|
56
BNP Paribas Financial Markets
Paris,
France
| $5.73K | +$6.83K | +452 | New |
|
57
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $64 | +$74.4K | +4,924 | +3,097% |
|
|
FCM
58
Farallon Capital Management
San Francisco,
California
| – | -$2.01M | -100,000 | Closed |
|
59
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$226K | -11,251 | Closed |
|
|
TRCT
60
Tower Research Capital (TRC)
New York
| – | -$122K | -6,058 | Closed |
|
|
VFA
61
Virtus Fund Advisers
Hartford,
Connecticut
| – | -$14K | -682 | Closed |
|
ALDR Hedge Fund Activity: Q3 2014 in Review
57 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q3 2014, worth a combined $163M — down 26% from $220M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ALDR positions and 4 closed out — a net gain of 8 holders — while 24 added to existing stakes and 14 trimmed.
The largest buyer was Jennison Associates, adding an estimated $17.2M. The largest seller was Franklin Resources, cutting an estimated $2.27M.
- 57 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q3 2014, up from 49 in Q2 2014.
- Funds reported $163M of Alder Biopharmaceuticals stock for Q3 2014, down 26% quarter-over-quarter.
- 12 funds opened new Alder Biopharmaceuticals positions in Q3 2014 and 4 closed out, a net change of +8 holders.
- The largest Alder Biopharmaceuticals buyer in Q3 2014 was Jennison Associates, an estimated $17.2M added.
- The largest Alder Biopharmaceuticals seller in Q3 2014 was Franklin Resources, an estimated $2.27M sold.
Based on aggregated 13F filings for Q3 2014.